The endogenous digitalis-like factor
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
8901463
DOI
10.1007/bf00240039
Knihovny.cz E-zdroje
- MeSH
- chemické jevy MeSH
- chemie MeSH
- digoxin * MeSH
- inhibitory enzymů chemie metabolismus MeSH
- kardenolidy MeSH
- krysa rodu Rattus MeSH
- lidé MeSH
- saponiny chemie metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- digoxin-like factors MeSH Prohlížeč
- digoxin * MeSH
- inhibitory enzymů MeSH
- kardenolidy MeSH
- saponiny MeSH
Intensive research into the presence of endogenous digitalis-like factor (EDLF) started shortly after identification of the alpha subunit of the Na,K,-ATPase as being receptor for digitalis glycosides. After years of skepticism, present data testify EDLF really exists. Most probably, the EDLF has chemical structure of either ouabain or of one of its isomers. It is secreted by the adrenal cortex, and, under conditions of stress, it's secretion is regulated differently from the secretion of both gluco- and mineralocorticoids. The physiological role of the EDLF has not been fully understood yet. In the newborn's kidneys, the inhibition of the Na,K-ATPase may assist to increase elimination of surplus sodium from the organism. In individuals of any age, the inhibitory influence of EDLF upon Na,K-ATPase in the arterial wall smooth muscle cells increases peripheral vascular resistance and thus, blood pressure. In the tissue culture, direct positive inotropic influences of EDLF upon rat cardiomyocytes was observed. However, the importance of positive inotropic effect of the EDLF upon the heart in clinical medicine remains to be elucidated.
Zobrazit více v PubMed
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63 PubMed
Cas Lek Cesk. 1980 Jul 11;119(27-28):768-70 PubMed
J Endocrinol. 1995 Sep;146(3):369-72 PubMed
Circulation. 1992 Aug;86(2):420-5 PubMed
Endocrinology. 1989 Nov;125(5):2573-9 PubMed
J Hypertens Suppl. 1985 Dec;3(3):S17-9 PubMed
Acta Endocrinol (Copenh). 1993 Jan;128(1):29-34 PubMed
Physiol Res. 1991;40(2):207-11 PubMed
Br Med J (Clin Res Ed). 1987 Mar 21;294(6574):729-32 PubMed
Physiol Bohemoslov. 1970;19(4):281-5 PubMed
Physiol Bohemoslov. 1981;30(4):289-94 PubMed
Eur J Pediatr. 1987 Mar;146(2):145-6 PubMed
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4661-3 PubMed
J Mol Cell Cardiol. 1981 Jan;13(1):107-10 PubMed
J Endocrinol Invest. 1990 Jan;13(1):9-12 PubMed
Clin Chim Acta. 1990 Nov 30;192(2):145-51 PubMed
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8189-93 PubMed
Virchows Arch Pathol Anat Physiol Klin Med. 1951;320(3):197-237 PubMed
Nature. 1980 Oct 23;287(5784):743-5 PubMed
Res Commun Chem Pathol Pharmacol. 1985 Sep;49(3):387-99 PubMed
Lancet. 1995 Nov 25;346(8987):1381-2 PubMed
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4658-60 PubMed
Am J Cardiol. 1991 Feb 15;67(5):443-4 PubMed
J Nucl Biol Med. 1992 Jan-Mar;36(1):41-5 PubMed
J Hypertens Suppl. 1984 Dec;2(3):S481-3 PubMed
Biochem Biophys Res Commun. 1992 Nov 16;188(3):1024-9 PubMed
J Diabet Complications. 1991 Apr-Sep;5(2-3):146-7 PubMed
Clin Exp Hypertens A. 1987;9(11):1733-44 PubMed
J Biol Chem. 1991 Jul 25;266(21):13672-8 PubMed
Pediatr Res. 1984 Nov;18(11):1097-9 PubMed
Eur J Biochem. 1993 Aug 15;216(1):261-8 PubMed
Biochem Pharmacol. 1981 Apr 1;30(7):805-6 PubMed
Endocrinology. 1988 Nov;123(5):2440-4 PubMed
Clin Sci (Lond). 1992 Jun;82(6):625-30 PubMed
Life Sci. 1982 May 24;30(21):1775-81 PubMed
Klin Wochenschr. 1982 Oct 1;60(19):1249-53 PubMed
Fed Proc. 1985 Sep;44(12):2806-11 PubMed
Clin Chem. 1992 Apr;38(4):504-6 PubMed
Cardiovasc Res. 1991 May;25(5):371-7 PubMed
Lancet. 1986 Mar 22;1(8482):689 PubMed
Hypertension. 1991 Jun;17(6 Pt 2):923-9 PubMed
Mol Pharmacol. 1980 Nov;18(3):402-5 PubMed
Eur J Pharmacol. 1993 Apr 6;234(2-3):165-72 PubMed
Physiol Bohemoslov. 1982;31(1):83-5 PubMed
Hypertension. 1994 Jan;23(1 Suppl):I102-5 PubMed
